Analysis of the results of the use of endovascular technologies in the treatment of patients with type 2 diabetes mellitus complicated by diabetic foot syndrome

Introduction. Revascularization for the neuroischemic form of diabetic foot syndrome is associated with difficulties in vascular reconstruction and a difficult postoperative course, due to the severe comorbidities in this patient population. Therefore, endovascular treatment of diabetic foot syndrome is rapidly becoming the treatment of choice for these patients, as lower extremity ischemia is a significant determinant of their mortality.

The purpose of the study. To analyze the results of revascularization interventions in the neuro-ischemic form of diabetic foot syndrome and identify ways to improve these results.

Materials and methods. The prospective study included 93 patients with ulcerative necrotic lesions of the feet and lower leg on the background of critical ischemia in the neuro-ischemic form of diabetic foot syndrome. The duration of diabetes mellitus in patients ranged from 1 month (diagnosed during examination for ulcerative necrotic lesions of the feet) to 41 years, the median was 12 years (the 25th percentile is 8 years, the 75th percentile is 20 years).

Research results and discussion. Successful treatment of patients with ulcerative necrotic foot lesions in the neuro-ischemic form of diabetic foot syndrome is possible in centers where conditions are available for angiographic examination, endovascular interventions, and vascular angioreconstructions. A multidisciplinary team with a wide range of possibilities for limb revascularization and wound treatment is the main factor in the successful treatment of patients with the neuro-ischemic form of diabetic foot syndrome.

Conclusion. The development of early diagnosis methods (before ulcerative necrotic foot lesions) and timely revascularization are promising areas for improving care for patients with the neuro-ischemic form of diabetic foot syndrome.

1. Waibel F.W.A., Uckay I., Soldevila-Boixader L., Sydler C., Gariani K. Current knowledge of morbidities and direct costs related to diabetic foot disorders: a literature review. Front. Endocrinol, 2024, no 14, pp. 1323315. https://doi.org/10.3389/fendo.2023.1323315

2. Peng B., Min R., Liao Y., Yu A. Development of predictive nomograms for clinical use to quantify the risk of amputation in patients with diabetic foot ulcer. Journal of Diabetes Research, 2021, pp. 6621035. https://doi.org/10.1155/2021/6621035

3. Mariadoss A.V.A., Sivakumar A.S., Lee C.H., Kim S.J. Diabetes mellitus and diabetic foot ulcer: Etiology, biochemical and molecular based treatment strategies via gene and nanotherapy. Biomedicine & pharmacotherapy, 2022, no 151, pp. 113134. https://doi.org/10.1016/j.biopha.2022.113134

4. Senneville E., Albalawi Z., Van Asten S.A., Abbas Z.G., Allison G., Aragon-Sanchez J. et al. IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes-related foot infections (IWGDF/IDSA 2023). Diabetes/metabolism research and reviews, 2024, no 40 (3), pp. e3687. https://doi.org/10.1002/dmrr.3687

5. Oliveira-Cortez A., Rodrigues Ferreira I., Luiza Nunes Abreu C., de Oliveira Bosco Y., Kummel Duarte C., Nogueira Cortez D. Incidence of the first diabetic foot ulcer: A systematic review and meta-analysis. Diabetes research and clinical practice, 2023, vol. 198, pp. 110594. https://doi.org/10.1016/j.diabres.2023.110594

6. Bellomo T.R., Lee S., McCarthy M., Tong K.P.S., Ferreira S.S., Cheung T.P., Rose-Sauld S. Management of the diabetic foot. Seminars in vascular surgery, 2022, no 35 (2), pp. 219–227. https://doi.org/10.1053/j.semvascsurg.2022.04.002

7. Aan de Stegge W.B., Schut M.C., Abu-Hanna A., van Baal J.G., van Netten J.J., Bus S.A. Development of a prediction model for foot ulcer recurrence in people with diabetes using easyto-obtain clinical variables. BMJ open diabetes research & care, 2021, no 9 (1), pp. 22–57. https://doi.org/10.1136/bmjdrc-2021-002257

8. Sorber R., Abularrage C.J. Diabetic foot ulcers: Epidemiology and the role of multidisciplinary care teams. Seminars in vascular surgery, 2021, no 34 (1), pp. 47–53. https://doi.org/10.1053/j.semvascsurg.2021.02.006

9. Morbach S., Eckhard M., Lobmann R., Muller E., Reike H., Risse A. et al. Diabetic foot syndrome. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2023, no 131, рр. 1–2, pp. 84–93. https://doi.org/10.1055/a-1946-3838

10. Armstrong D.G., Tan T.W., Boulton A.J.M., Bus S.A. Diabetic foot ulcers: a review. JAMA, 2023, no 330 (1), pp. 62–75. https://doi.org/10.1001/jama.2023.10578

11. Kairys A., Pauliukiene R., Raudonis V., Ceponis J. Towards home-based diabetic foot ulcer monitoring: a systematic review. Sensors (Basel, Switzerland), 2023, no 23 (7), pp. 3618. https://doi.org/10.3390/s23073618

12. Rehman Z.U., Khan J., Noordin S. Diabetic foot ulcers: Contemporary assessment and management. JPMA. The Journal of the Pakistan Medical Association, 2023, no 73 (7), pp. 1480–1487. https://doi.org/10.47391/JPMA.6634

13. Schaper N.C. Diabetic foot ulcer classification system for research purposes: a progress report on criteria for including patients in research studies. Diabetes/metabolism research and reviews, 2004, no 20 (Suppl. 1), pp. S90–S95. https://doi.org/10.1002/dmrr.464

14. Apelqvist J., Bakker K., van Houtum W.H., Nabuurs-Franssen M.H., Schaper N.C. International consensus and practical guidelines on the management and the prevention of the diabetic foot. International Working Group on the Diabetic Foot. Diabetes/metabolism research and reviews, 2000, no 16 (Suppl. 1), pp. S84–S92. https://doi.org/10.1002/1520-7560(200009/10)16:1